Modulation of daunorubicin toxicity by liposomal encapsulation and use of specific inhibitors in vitro.

No abstract is available for this paper.

• Publication year

  2000

• Venue

  Toxicology

• Publication date

  2000-04-03

• Fields of study

  Medicine, Chemistry

• Identifiers
  DOI 10.1016/S0300-483X(99)00206-1PMID 10781887
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Multidrug resistance in cancer chemotherapy

  2004cited by this paper
• Development of daunorubicin resistance in tumour cells by induction of carbonyl reduction.

  2000cited by this paper
• Induction of daunorubicin carbonyl reducing enzymes by daunorubicin in sensitive and resistant pancreas carcinoma cells.

  1996cited by this paper
• Monohydroxyethylrutoside as protector against chronic doxorubicin‐induced cardiotoxicity

  1995cited by this paper
• Failure of liposomal encapsulation of doxorubicin to circumvent multidrug resistance in an in vitro model of rat glioblastoma cells.

  1995cited by this paper
• Reduction of drug ketones by dihydrodiol dehydrogenases, carbonyl reductase and aldehyde reductase of human liver.

  1995cited by this paper
• Modulation of daunorubicin intracellular accumulation in P-glycoprotein expressing MCF-7 human breast adenocarcinoma cells by thermosensitive-liposome encapsulation and hyperthermia.

  1995cited by this paper
• Intrinsic cellular resistance to oxazaphosphorines exhibited by a human colon carcinoma cell line expressing relatively large amounts of a class-3 aldehyde dehydrogenase.

  1994cited by this paper
• Liposomal daunorubicin treatment of HIV-associated Kaposi's sarcoma.

  1993cited by this paper
• Liposomes as carriers of cancer chemotherapy. Current status and future prospects.

  1993cited by this paper
• Cellular detoxification of tripeptidyl aldehydes by an aldo-keto reductase.

  1993cited by this paper
• Initial clinical (phase I) trial of TLC D-99 (doxorubicin encapsulated in liposomes).

  1993cited by this paper
• Expression of several resistance mechanisms in untreated human kidney and lung carcinomas.

  1992cited by this paper
• Liposome-mediated modulation of multidrug resistance in human HL-60 leukemia cells.

  1992cited by this paper
• Agents which reverse multidrug-resistance are inhibitors of [3H]vinblastine transport by isolated vesicles.

  1991cited by this paper
• Characterization of liposomal systems containing doxorubicin entrapped in response to pH gradients.

  1990cited by this paper
• Elevated pentose cycle and glucuronyltransferase in daunorubicin-resistant P388 cells.

  1990cited by this paper
• Influence of vesicle size, lipid composition, and drug-to-lipid ratio on the biological activity of liposomal doxorubicin in mice.

  1989cited by this paper
• Re-examination and further development of a precise and rapid dye method for measuring cell growth/cell kill.

  1989cited by this paper
• The biochemistry of P-glycoprotein-mediated multidrug resistance.

  1989cited by this paper
• Role of the glutathione redox cycle in acquired and de novo multidrug resistance.

  1988cited by this paper
• Multifactorial resistance to adriamycin: relationship of DNA repair, glutathione transferase activity, drug efflux, and P-glycoprotein in cloned cell lines of adriamycin-sensitive and -resistant P388 leukemia.

  1988cited by this paper
• Markedly reduced levels of anthracycline-induced DNA strand breaks in resistant P388 leukemia cells and isolated nuclei.

  1987cited by this paper
• Overexpression of a novel anionic glutathione transferase in multidrug-resistant human breast cancer cells.

  1986cited by this paper
• Protective effects of O-(beta-hydroxyethyl)-rutosides (HR) against adriamycin-induced toxicity in rats.

  1985cited by this paper
• Verapamil restoration of daunorubicin responsiveness in daunorubicin-resistant Ehrlich ascites carcinoma.

  1982cited by this paper
• Purification and properties of an NADPH-dependent carbonyl reductase from human brain. Relationship to prostaglandin 9-ketoreductase and xenobiotic ketone reductase.

  1981cited by this paper
• The effects of aldose reductase inhibitors on the metabolism of cultured monkey kidney epithelial cells.

  1981cited by this paper

• Rutin Ameliorates Acrylamide-Induced Hepatotoxicity and Biochemical Disturbance in Male Albino Rats

  2018influential citation
• Surfactant-based drug delivery systems for treating drug-resistant lung cancer

  2016cites this paper
• pH-Responsive therapeutic solid lipid nanoparticles for reducing P-glycoprotein-mediated drug efflux of multidrug resistant cancer cells

  2015cites this paper
• Investigation of cytotoxic, apoptosis-inducing, genotoxic and protective effects of the flavonoid rutin in HTC hepatic cells.

  2011cites this paper
• Investigation of cytotoxic , apoptosis-inducing , genotoxic and protective effects of the flavonoid rutin in HTC hepatic cells

  2010influential citation
• The Metabolism and Disposition of the Oral Dipeptidyl Peptidase-4 Inhibitor, Linagliptin, in Humans

  2010cites this paper
• Effects of stealth liposomal daunorubicin plus tamoxifen on the breast cancer and cancer stem cells.

  2010cites this paper
• Novel formulation approaches for optimising delivery of anticancer drugs based on P-glycoprotein modulation.

  2009cites this paper
• [Liposomal daunorubicine combined with cytarabine in the treatment of relapsed/refractory acute myeloid leukemia in children].

  2002cites this paper
• Effektive Rezidivtherapie der akuten myeloischen Leukämie im Kindesalter mit liposomalem Daunorubicin und Cytarabin

  2002cites this paper
• The combined effect of IDA and glutaraldehyde on the properties of human erythrocytes.

  2001cites this paper
• Literature alerts.

  2000cites this paper